my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
15-05-2012: Amakem NV announced the appointment of Dr. Steve Pakola as Chief Medical Officer and Dr. George Lasezkay to its Board as an Independent Director. Both have exceptional track records in the biotechnology industry and bring a wealth of ophthalmology experience to Amakem.
Dr. Pakola was previously Chief Medical Officer at ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, where he played a pivotal role in driving the development of ThromboGenics’ lead product, ocriplasmin, from initial concept through to regulatory submission.
Dr. Lasezkay was previously Corporate Vice President of Corporate Development and Assistant General Counsel for Allergan, Inc., a global pharmaceutical and medical aesthetics company. In these positions, he was responsible for corporate strategy as well as licensing, R&D collaboration and acquisition transactions involving both products and companies. George is currently an industry consultant and serves as an advisor to a number of public and private biotechnology companies developing therapies for ophthalmic conditions.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Amakem Appoints Maarten van Geffen as Head of CMC and Operations
Amakem NV announced the appointment of Maarten van Geffen as Head of CMC and Operations. Mr. van Geffen brings an exceptional track record in international management experience in pharmaceutical development to Amakem.Mr. Maarten van Geffen’s career in the industry spans nearly 25 years, wi ... more
Amakem Appoints Dr. Steve Pakola as Chief Medical Officer
Amakem NV announced the appointment of Dr. Steve Pakola as Chief Medical Officer and Dr. George Lasezkay to its Board as an Independent Director. Both have exceptional track records in the biotechnology industry and bring a wealth of ophthalmology experience to Amakem.Dr. Pakola was previou ... more
Amakem and Devgen announced the closure of a EUR 1.5 million seed financing round and the contribution in kind of certain assets, intellectual property and know-how of Devgen's former pharma division. The financing round was led by LRM, through its ARKIV subsidiary KMOFIN. Other investors ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
